Polymer-based drug delivery devices for neurological disorders

CNS and Neurological Disorders - Drug Targets

Volumn 8, Issue 3, 2009, Pages 205-221

  Halliday, A J ^a   Cook, Mark J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BIONIC EAR INSTITUTE   (Australia)

Author keywords

Alzheimer's disease; Drug delivery; Epilepsy; Huntington's disease; Implantable devices; Neurological disorders; Parkinson's disease; Polymer

Indexed keywords

ANTICONVULSIVE AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CLONAZEPAM; DIAZEPAM; DIZOCILPINE; DOPAMINE; ETHYLENE VINYL ACETATE COPOLYMER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; MICROSPHERE; NERVE GROWTH FACTOR; POLYGLACTIN; POLYMER;

ALZHEIMER DISEASE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE IMPLANT; CONTROLLED DRUG RELEASE; DEGENERATIVE DISEASE; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG IMPLANT; DRUG IMPLANTATION; DRUG PELLET; EPILEPSY; EXCIPIENT COMPATIBILITY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SAFETY;

EID: 70349499036     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152709788680698     Document Type: Review

References (125)

1. World Health Organisation. Neurological Disorders: Public Health Challenges, World Health Organisation Press: Geneva, 2006; p. 218.
2. Shorvon, S.D. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia, 1996, 37(s2), S1-3.
3. Kienbacher, C.; Wöber, C.; Zesch, H.E.; Hafferl-Gattermayer, A.; Posch, M.; Karwautz, A.; Zormann, A.; Berger, G.; Zebenholzer, K.; Konrad, A.; Wöber-Bingöl, Ç. Clinical features, classification and prognosis of migraine and tension-type headache in children and adolescents: a long-term follow-up study. Cephalalgia, 2006, 26(7), 820-30.
4. Abbott, N.J.; Ronnback, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci., 2006, 7(1), 41-53.
5. Klitgaard, H.; Matagne, A.; Grimee, R.; Vanneste-Goemaere, J.; Margineanu, D.G. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure, 2003, 12(2), 92-100.
6. Eder, H.G.; Stein, A.; Fisher, R.S. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res., 1997, 29(1), 17-24.
7. Brailowsky, S.; Silva-Barrat, C.; Ménini, C.; Riche, D.; Naquet, R. Effects of localized, chronic GABA infusions into different cortical areas of the photosensitive baboon, Papio papio. Electroencephalogr. Clin. Neurophysiol., 1989, 72(2), 147-56.
8. Serralta, A.; Barcia, J.A.; Ortiz, P.; Duran, C.; Hernandez, M.E.; Alos, M. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model. Epilepsy Res., 2006, 70(1), 15-26.
9. Barcia, J.A.; Rubio, P.; Alos, M.; Serralta, A.; Belda, V. Anticonvulsant and neurotoxic effects of intracerebroventricular injection of phenytoin, phenobarbital and carbamazepine in an amygdala-kindling model of epilepsy in the rat. Epilepsy Res,. 1999, 33(2-3), 159-67.
10. Gonzalez-Darder, J.M.; Garcia-Teno, M. Anticonvulsant effect of intraventricular antiepileptic drugs. Experimental study. Neurol. Res. 1995, 17(3), 190-2.
11. Chae, G.S.; Lee, J.S.; Kim, S.H.; Seo, K.S.; Kim, M.S.; Lee, H.B.; Khang, G. Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. Int. J. Pharm., 2005, 301(1-2), 6-14.
12. Fournier, E.; Passirani, C.; Colin, N.; Breton, P.; Sagodira, S.; Benoit, J.P. Development of novel 5-FU-loaded poly(methylidene malonate 2.1.2)-based microspheres for the treatment of brain cancers. Eur. J. Pharm. Biopharm., 2004, 57(2), 189-97.
13. Gallia, G.L.; Brem, S.; Brem, H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J. Natl. Compr. Canc. Netw., 2005, 3(5), 721-8.
14. Traitel, T.; Cohen, Y.; Kost, J. Characterization of glucose-sensitive insulin release systems in simulated in vivo conditions. Biomaterials, 2000, 21(16), 1679-87.
15. Packhaeuser, C.B.; Kissel, T. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-coglycolide) nanoparticles. J. Control. Release, 2007, 123(2), 131-40.
16. Zhang, K.; Wu, X.Y. Modulated insulin permeation across a glucose-sensitive polymeric composite membrane. J. Control. Release, 2002, 80(1-3), 169-78.
17. Zhang, Y.; Guan, Y.; Zhou, S. Permeability control of glucose-sensitive nanoshells. Biomacromolecules, 2007, 8(12), 3842-7.
18. Domb, A.J.; Rock, M.; Perkin, C.; Yipchuck, G.; Broxup, B.; Villemure, J.G. Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. Biomaterials, 1995, 16(14), 1069-72.
19. Popovic, N.; Brundin, P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharm., 2006, 314(2), 120-6.
20. Harbaugh, R.E. Novel CNS-directed drug delivery systems in Alzheimer's disease and other neurological disorders. Neurobiol. Aging, 1989, 10(5), 623-9.
21. Peterson, G.M. Sustained and controlled release of neuroactive substances in the CNS by encapsulation into implantable polymers. Neurobiol. Aging, 1989, 10(5), 639-40, discussion 648-50.
22. Haik-Creguer, K.L.; Dunbar, G.L.; Sabel, B.A.; Schroeder, U. Small drug sample fabrication of controlled release polymers using the microextrusion method. J. Neurosci. Methods, 1998, 80(1), 37-40.
23. Yoshida, M.; Ohkoshi, N.; Tsuru, N. Effects of acute treatment and long-term treatment with MK-801 against amygdaloid kindled seizures in rats. Epilepsy Res., 1997, 26(3), 407-13.
24. Smith, A.L.; Cordery, P.M.; Thompson, I.D. Manufacture and release characteristics of Elvax polymers containing glutamate receptor antagonists. J. Neurosci. Methods, 1995, 60(1-2), 211-7.
25. Kokaia, M.; Aebischer, P.; Elmer, E.; Bengzon, J.; Kalen, P.; Kokaia, Z.; Lindvall, O. Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenalinereleasing polymer matrices. Exp. Brain Res., 1994, 100(3), 385-94.
26. Tamargo, R.J.; Rossell, L.A.; Kossoff, E.H.; Tyler, B.M.; Ewend, M.G.; Aryanpur, J.J. The intracerebral administration of phenytoin using controlled-release polymers reduces experimental seizures in rats. Epilepsy Res., 2002, 48(3), 145-55.
27. Boison, D.; Scheurer, L.; Tseng, J.L.; Aebischer, P.; Mohler, H. Seizure suppression in kindled rats by intraventricular grafting of an adenosine releasing synthetic polymer. Exp. Neurol., 1999, 160(1), 164-74.
28. Shimono, N.; Ueda, M.; Nakamura, Y. Design of controlled release system with multi-layers of powder. Chem. Pharm. Bull. (Tokyo), 2002, 50(9), 1169-75.
29. Smith, J.S.; Macrae, R.J.; Snowden, M.J. Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads. Eur. J. Pharm. Biopharm., 2005, 60(1), 73-80.
30. Wilz, A.; Pritchard, E.M.; Li, T.; Lan, J.Q.; Kaplan, D.L.; Boison, D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials, 2008, 29(26), 3609-16.
31. Cho, C.S.; Han, S.Y.; Ha, J.H.; Kim, S.H.; Lim, D.Y. Clonazepam release from bioerodible hydrogels based on semi-interpenetrating polymer networks composed of poly(epsilon-caprolactone) and poly(ethylene glycol) macromer. Int. J. Pharm., 1999, 181(2), 235-42.
32. Kubek, M.J.; Liang, D.; Byrd, K.E.; Domb, A.J. Prolonged seizure suppression by a single implantable polymeric-TRH microdisk preparation. Brain Res., 1998, 809(2), 189-97.
33. Berrabah, M.; Andre, D.; Prevot, F.; Orecchioni, A.M.; Lafont, O. GC-MS determination of phenobarbitone entrapped in poly-epsilon-caprolactone nanocapsules. J. Pharm. Biomed. Anal., 1994, 12(3), 373-8.
34. Rane, Y.M.; Mashru, R.C.; Sankalia, M.G.; Sutariya, V.B.; Shah, P.P. Investigations on factors affecting chitosan for dissolution enhancement of oxcarbazepine by spray dried microcrystal formulation with an experimental design approach. Drug Dev. Ind. Pharm., 2007, 33(9), 1008-23.
35. Patterson, J.E.; James, M.B.; Forster, A.H.; Rades, T. Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone/vinyl acetate copolymers. Drug Dev. Ind. Pharm., 2008, 34(1), 95-106.
36. Filipovic-Grcic, J.; Perissutti, B.; Moneghini, M.; Voinovich, D.; Martinac, A.; Jalsenjak, I. Spray-dried carbamazepine-loaded chitosan and HPMC microspheres: preparation and characterisation. J. Pharm. Pharmacol., 2003, 55(7), 921-31.
37. Haznedar, S.; Dortunc, B. Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int. J. Pharm., 2004, 269(1), 131-40.
38. Duarte, A.R.; Roy, C.; Vega-Gonzalez, A.; Duarte, C.M.; Subra-Paternault, P. Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques. Int. J. Pharm., 2007, 332(1-2), 132-9.
39. Barakat, N.S.; Radwan, M.A. In vitro performance of carbamazepine loaded to various molecular weights of poly (D,L-lactide-co-glycolide). Drug Deliv. 2006, 13(1), 9-18.
40. Barakat, N.S.; Yassin, A.E. In vitro characterization of carbamazepine-loaded precifac lipospheres. Drug Deliv. 2006, 13(2), 95-104.
41. Ferranti, V.; Marchais, H.; Chabenat, C.; Orecchioni, A.M.; Lafont, O. Primidone-loaded poly-epsilon-caprolactone nanocapsules: incorporation efficiency and in vitro release profiles. Int. J. Pharm., 1999, 193(1), 107-11.
42. Fresta, M.; Cavallaro, G.; Giammona, G.; Wehrli, E.; Puglisi, G. Preparation and characterization of polyethyl-2-cyanoacrylate nanocapsules containing antiepileptic drugs. Biomaterials, 1996, 17(8), 751-8.
43. Montanari, L.; Cilurzo, F.; Valvo, L.; Faucitano, A.; Buttafava, A.; Groppo, A.; Genta, I.; Conti, B. Gamma irradiation effects on stability of poly(lactide-co-glycolide) microspheres containing clonazepam. J. Control. Release, 2001, 75(3), 317-30.
44. Passerini, N.; Perissutti, B.; Moneghini, M.; Voinovich, D.; Albertini, B.; Cavallari, C.; Rodriguez, L. Characterization of carbamazepine-Gelucire 50/13 microparticles prepared by a spray-congealing process using ultrasounds. J. Pharm. Sci., 2002, 91(3), 699-707.
45. Gavini, E.; Hegge, A.B.; Rassu, G.; Sanna, V.; Testa, C.; Pirisino, G.; Karlsen, J.; Giunchedi, P. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int. J. Pharm., 2006, 307(1), 9-15.
46. Dong, W.Y.; Maincent, P.; Bodmeier, R. In vitro and in vivo evaluation of carbamazepine-loaded enteric microparticles. Int. J. Pharm. 2007, 331(1), 84-92.
47. Giannola, L.I.; De Caro, V.; Di Stefano, V.; Rizzo, M.C. In vitro evaluation of cumulative release of valproic acid and vitamin E from hexadecanol microspheres. Part 2: antiepileptic agents. Pharmazie, 1993, 48(12), 917-20.
48. Friese, A.; Seiller, E.; Quack, G.; Lorenz, B.; Kreuter, J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm., 2000, 49(2), 103-9.
49. Ryu, J.; Jeong, Y.I.; Kim, I.S.; Lee, J.H.; Nah, J.W.; Kim, S.H. Clonazepam release from core-shell type nanoparticles of poly(epsilon-caprolactone)/poly(ethylene glycol)/ poly(epsilon-caprolactone) triblock copolymers. Int. J. Pharm., 2000, 200(2), 231-42.
50. Jeong, Y.I.; Cheon, J.B.; Kim, S.H.; Nah, J.W.; Lee, Y.M.; Sung, Y.K.; Akaike, T.; Cho, C.S. Clonazepam release from core-shell type nanoparticles in vitro. J. Control. Release, 1998, 51(2-3), 169-78.
51. Jeong, Y.I.; Nah, J.W.; Na, H.K.; Na, K.; Kim, I.S.; Cho, C.S.; Kim, S.H. Self-assembling nanospheres of hydrophobized pullulans in water. Drug Dev. Ind. Pharm., 1999, 25(8), 917-27.
52. Benelli, P.; Conti, B.; Genta, I.; Costantini, M.; Montanari, L. Clonazepam microencapsulation in poly-D,L-lactide-co-glycolide microspheres. J. Microencapsul., 1998, 15(4), 431-43.
53. Nah, J.W.; Paek, Y.W.; Jeong, Y.I.; Kim, D.W.; Cho, C.S.; Kim, S.H.; Kim, M.Y. Clonazepam release from poly(DL-lactide-coglycolide) nanoparticles prepared by dialysis method. Arch. Pharm. Res., 1998, 21(4), 418-22.
54. Li, Z.; Li, Q.; Simon, S.; Guven, N.; Borges, K.; Youan, B.B. Formulation of spray-dried phenytoin loaded poly(epsilon-caprolactone) microcarrier intended for brain delivery to treat epilepsy. J. Pharm. Sci., 2007, 96(5), 1018-30.
55. Chen, J.; Davis, S.S. The release of diazepam from poly(hydroxybutyrate-hydroxyvalerate) microspheres. J. Microencapsul., 2002, 19(2), 191-201.
56. Yasuhara, T.; Shingo, T.; Date, I. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med. Okayama, 2007, 61(2), 51-6.
57. Kordower, J.H.; Palfi, S.; Chen, E.Y.; Ma, S.Y.; Sendera, T.; Cochran, E.J.; Mufson, E.J.; Penn, R.; Goetz, C.G.; Comella, C.D. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol., 1999, 46(3), 419-24.
58. Becker, J.B.; Robinson, T.E.; Barton, P.; Sintov, A.; Siden, R.; Levy, R.J. Sustained behavioral recovery from unilateral nigrostriatal damage produced by the controlled release of dopamine from a silicone polymer pellet placed into the denervated striatum. Brain Res., 1990, 508(1), 60-4.
59. Sabel, B.A.; Dominiak, P.; Huaser, W.; During, M.J.; Freese, A. Extended levodopa release from a subcutaneously implanted polymer matrix in rats. Ann. Neurol., 1990, 28(5), 714-7.
60. Sabel, B.A.; Dominiak, P.; Hauser, W.; During, M.J.; Freese, A. Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats. J. Pharmacol. Exp. Ther., 1990, 255(2), 914-22.
61. Freese, A.; Sabel, B.A.; Saltzman, W.M.; During, M.J.; Langer, R. Controlled release of dopamine from a polymeric brain implant: in vitro characterization. Exp. Neurol., 1989, 103(3), 234-8.
62. During, M.J.; Freese, A.; Sabel, B.A.; Saltzman, W.M.; Deutch, A.; Roth, R.H.; Langer, R. Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann. Neurol., 1989, 25(4), 351-6.
63. Sabel, B.A.; Freese, A.; During, M.J. Controlled-release dopamine polymers as a novel approach to the treatment of Parkinson's disease. Adv. Neurol., 1990, 53, 513-8.
64. Winn, S.R.; Wahlberg, L.; Tresco, P.A.; Aebischer, P. An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats. Exp. Neurol., 1989, 105(3), 244-50.
65. Bensadoun, J.C.; Pereira de Almeida, L.; Fine, E.G.; Tseng, J.L.; Deglon, N.; Aebischer, P. Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. J. Control Release, 2003, 87(1-3), 107-15.
66. Wang, J.; Bankiewicz, K.S.; Plunkett, R.J.; Oldfield, E.H. Intrastriatal implantation of interleukin-1: reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain. J. Neurosurg., 1994, 80(3), 484-90.
67. McRae-Degueurce, A.; Hjorth, S.; Dillon, D.L.; Mason, D.W.; Tice, T.R. Implantable microencapsulated dopamine (DA): a new approach for slow-release DA delivery into brain tissue. Neurosci. Lett., 1988, 92(3), 303-9.
68. During, M.J.; Freese, A.; Deutch, A.Y.; Kibat, P.G.; Sabel, B.A.; Langer, R.; Roth, R.H. Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp. Neurol. 1992, 115(2), 193-9.
69. McRae, A.; Hjorth, S.; Mason, D.; Dillon, L.; Tice, T. Implantable microencapsulated dopamine (DA): prolonged functional release of DA in denervated striatal tissue. J. Neural Transm. Suppl., 1990, 29, 207-15.
70. McRae, A.; Dahlstrom, A. Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA induced parkinsonism. Neurochem. Int., 1994, 25(1), 27-33.
71. McRae, A.; Hjorth, S.; Mason, D.W.; Dillon, L.; Tice, T.R. Microencapsulated dopamine (DA)-induced restitution of function in 6-OHDA-denervated rat striatum in vivo: comparison between two microsphere excipients. J. Neural Transplant. Plast., 1991, 2(3-4), 165-73.
72. McRae, A.; Ling, E.A.; Hjorth, S.; Dahlstrom, A.; Mason, D.; Tice, T. Catecholamine-containing biodegradable microsphere implants as a novel approach in the treatment of CNS neurodegenerative disease: a review of experimental studies in DA-lesioned rats. Mol. Neurobiol., 1994, 9(1-3), 191-205.
73. Arica, B.; Kas, H.S.; Moghdam, A.; Akalan, N.; Hincal, A.A. Carbidopa/ levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats. J. Control Release, 2005, 102(3), 689-97.
74. Andrieu-Soler, C.; Aubert-Pouessel, A.; Doat, M.; Picaud, S.; Halhal, M.; Simonutti, M.; Venier-Julienne, M.C.; Benoit, J.P.; Behar-Cohen, F. Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol. Vis., 2005, 11, 1002-11.
75. Aubert-Pouessel, A.; Venier-Julienne, M.C.; Clavreul, A.; Sergent, M.; Jollivet, C.; Montero-Menei, C.N.; Garcion, E.; Bibby, D.C.; Menei, P.; Benoit, J.P. In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control Release, 2004, 95(3), 463-75.
76. Garbayo, E.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. Eur. J. Pharm. Biopharm., 2008, 69(3), 844-51.
77. Jollivet, C.; Aubert-Pouessel, A.; Clavreul, A.; Venier-Julienne, M.C.; Remy, S.; Montero-Menei, C.N.; Benoit, J.P.; Menei, P. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials, 2004, 25(5), 933-42.
78. Gouhier, C.; Chalon, S.; Aubert-Pouessel, A.; Venier-Julienne, M.C.; Jollivet, C.; Benoit, J.P.; Guilloteau, D. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease. Synapse, 2002, 44(3), 124-31.
79. Jollivet, C.; Aubert-Pouessel, A.; Clavreul, A.; Venier-Julienne, M.C.; Montero-Menei, C.N.; Benoit, J.P.; Menei, P. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. Neurosci. Lett., 2004, 356(3), 207-10.
80. Senthilkumar, K.S.; Saravanan, K.S.; Chandra, G.; Sindhu, K.M.; Jayakrishnan, A.; Mohanakumar, K.P. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemiparkinsonism. Behav. Brain Res., 2007, 184(1), 11-8.
81. Gratacos, E.; Perez-Navarro, E.; Tolosa, E.; Arenas, E.; Alberch, J. Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members. J. Neurochem., 2001, 78(6), 1287-96.
82. Perez-Navarro, E.; Alberch, J. Protective role of nerve growth factor against excitatory amino acid injury during neostriatal cholinergic neurons postnatal development. Exp. Neurol., 1995, 135(2), 146-52.
83. Araujo, D.M.; Hilt, D.C. Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience, 1998, 82(1), 117-27.
84. Araujo, D.M.; Hilt, D.C. Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience, 1997, 81(4), 1099-110.
85. Davies, S.W.; Beardsall, K. Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones. Neurosci. Lett., 1992, 140(2), 161-4.
86. Anderson, K.D.; Panayotatos, N.; Corcoran, T.L.; Lindsay, R.M.; Wiegand, S.J. Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc. Natl. Acad. Sci. USA, 1996, 93(14), 7346-51.
87. Perez-Navarro, E.; Canudas, A.M.; Akerund, P.; Alberch, J.; Arenas, E. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent the death of striatal projection neurons in a rodent model of Huntington's disease. J. Neurochem., 2000, 75(5), 2190-9.
88. Perez-Navarro, E.; Alberch, J.; Neveu, I.; Arenas, E. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience, 1999, 91(4), 1257-64.
89. Fischer, W.; Sirevaag, A.; Wiegand, S.J.; Lindsay, R.M.; Bjorklund, A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4/5 but not by brain-derived neurotrophic factor. Proc. Natl. Acad. Sci., USA, 1994, 91(18), 8607-11.
90. Fischer, W.; Wictorin, K.; Bjorklund, A.; Williams, L.R.; Varon, S.; Gage, F.H. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature, 1987, 329(6134), 65-8.
91. Tuszynski, M.H. Intraparenchymal NGF infusions rescue degenerating cholinergic neurons. Cell Transplant., 2000, 9(5), 629-36.
92. Williams, B.J.; Eriksdotter-Jonhagen, M.; Granholm, A.C. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease. Prog. Neurobiol., 2006, 80(3), 114-28.
93. Eriksdotter Jonhagen, M.; Nordberg, A.; Amberla, K.; Backman, L.; Ebendal, T.; Meyerson, B.; Olson, L.; Seiger; Shigeta, M.; Theodorsson, E.; Viitanen, M.; Winblad, B.; Wahlund, L.O. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 1998, 9(5), 246-57.
94. Olson, L.; Nordberg, A.; von Holst, H.; Backman, L.; Ebendal, T.; Alafuzoff, I.; Amberla, K.; Hartvig, P.; Herlitz, A.; Lilja, A. Nerve growth factor affects 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J. Neural Transm. Park. Dis. Dement. Sect., 1992, 4(1), 79-95.
95. Hagg, T.; Manthorpe, M.; Vahlsing, H.L.; Varon, S. Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage. Exp. Neurol., 1988, 101(2), 303-12.
96. Hagg, T.; Varon, S. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl. Acad. Sci. USA, 1993, 90(13), 6315-9.
97. Saltzman, W.M.; Mak, M.W.; Mahoney, M.J.; Duenas, E.T.; Cleland, J.L. Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharm. Res., 1999, 16(2), 232-40.
98. Krewson, C.E.; Klarman, M.L.; Saltzman, W.M. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res., 1995, 680(1-2), 196-206.
99. Hoffman, D.; Wahlberg, L.; Aebischer, P. NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion. Exp. Neurol., 1990, 110(1), 39-44.
100. Powell, E.M.; Sobarzo, M.R.; Saltzman, W.M. Controlled release of nerve growth factor from a polymeric implant. Brain Res., 1990, 515(1-2), 309-11.
101. Krewson, C.E.; Dause, R.; Mak, M.; Saltzman, W.M. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomater. Sci. Polym. Ed., 1996, 8(2), 103-17.
102. Yamamoto, S.; Yoshimine, T.; Fujita, T.; Kuroda, R.; Irie, T.; Fujioka, K.; Hayakawa, T. Protective effect of NGF atelocollagen mini-pellet on the hippocampal delayed neuronal death in gerbils. Neurosci. Lett., 1992, 141(2), 161-5.
103. Johnson, P.J.; Skornia, S.L.; Stabenfeldt, S.E.; Willits, R.K. Maintaining bioactivity of NGF for controlled release from PLGA using PEG. J. Biomed. Mater. Res. A, 2008, 86(2), 420-7.
104. Burdick, J.A.; Ward, M.; Liang, E.; Young, M.J.; Langer, R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials, 2006, 27(3), 452-9.
105. Howard, M.A.; 3rd; Gross, A.; Grady, M.S.; Langer, R.S.; Mathiowitz, E.; Winn, H.R.; Mayberg, M.R. Intracerebral drug delivery in rats with lesion-induced memory deficits. J. Neurosurg., 1989, 71(1), 105-12.
106. Menei, P.; Pean, J.M.; Nerriere-Daguin, V.; Jollivet, C.; Brachet, P.; Benoit, J.P. Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Exp. Neurol., 2000, 161(1), 259-72.
107. Pean, J.M.; Boury, F.; Venier-Julienne, M.C.; Menei, P.; Proust, J.E.; Benoit, J.P. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm. Res., 1999, 16(8), 1294-9.
108. Pean, J.M.; Venier-Julienne, M.C.; Boury, F.; Menei, P.; Denizot, B.; Benoit, J.P. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control Release, 1998, 56(1-3), 175-87.
109. Camarata, P.J.; Suryanarayanan, R.; Turner, D.A.; Parker, R.G.; Ebner, T.J. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery, 1992, 30(3), 313-9.
110. Gouhier, C.; Chalon, S.; Venier-Julienne, M.C.; Bodard, S.; Benoit, J.; Besnard, J.; Guilloteau, D. Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide. Neurosci. Lett., 2000, 288(1), 71-5.
111. Pean, J.M.; Menei, P.; Morel, O.; Montero-Menei, C.N.; Benoit, J.P. Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials, 2000, 21(20), 2097-101.
112. Xu, X.; Yu, H.; Gao, S.; Ma, H.Q.; Leong, K.W.; Wang, S. Polyphosphoester microspheres for sustained release of biologically active nerve growth factor. Biomaterials, 2002, 23(17), 3765-72.
113. Maysinger, D.; Jalsenjak, I.; Cuello, A.C. Microencapsulated nerve growth factor: effects on the forebrain neurons following devascularizing cortical lesions. Neurosci. Lett., 1992, 140(1), 71-4.
114. Riddle, D.R.; Katz, L.C.; Lo, D.C. Focal delivery of neurotrophins into the central nervous system using fluorescent latex microspheres. Biotechniques, 1997, 23(5), 928-34, 936-7.
115. Maysinger, D.; Krieglstein, K.; Filipovic-Grcic, J.; Sendtner, M.; Unsicker, K.; Richardson, P. Microencapsulated ciliary neurotrophic factor: physical properties and biological activities. Exp. Neurol., 1996, 138(2), 177-88.
116. Nkansah, M.K.; Tzeng, S.Y.; Holdt, A.M.; Lavik, E.B. Poly(lacticco-glycolic acid) nanospheres and microspheres for short- and long-term delivery of bioactive ciliary neurotrophic factor. Biotechnol. Bioeng., 2008, 100(5), 1010-9.
117. Mittal, S.; Cohen, A.; Maysinger, D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuroreport, 1994, 5(18), 2577-82.
118. Mocchetti, I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell. Mol. Life Sci., 2005, 62(19-20), 2283-94.
119. Maysinger, D.; Garofalo, L.; Jalsenjak, I.; Cuello, A.C. Effects of microencapsulated monosialoganglioside GM1 on cholinergic neurons. Brain Res., 1989, 496(1-2), 165-72.
120. Maysinger, D.; Jalsenjak, V.; Stolnik, S.; Garofalo, L.; Cuello, A. C.; Jalsenjak, I. Microencapsulated monosialoganglioside GM1: physical properties and in vivo effects. J. Microencapsul., 1989, 6(1), 35-42.
121. Maysinger, D.; Herrera-Marschitz, M.; Ungerstedt, U.; Cuello, A.C. Effects of treatment with microencapsulated monosialoganglioside GM1 on cortical and striatal acetylcholine release in rats with cortical devascularizing lesions. Neurosci. Lett., 1990, 118(2), 252-6.
122. Krzeminski, J.P.; Piquer, J.; Riesgo, P. Repeated implantation of interstitial chemotherapy to treat malignant gliomas. Neurosurg. Q., 2008, 18(4), 286-9.
123. Thanou, M.; Duncan, R. Polymer-protein and polymer-drug conjugates in cancer therapy. Curr. Opin. Investig. Drugs, 2003, 4(6), 701-9.
124. Van Gompel, J.J.; Stead, S.M.; Giannini, C.; Meyer, F.B.; Marsh, W.R.; Fountain, T.; So, E.; Cohen-Gadol, A.; Lee, K.H.; Worrell, G.A. Phase I trial: safety and feasibility of intracranial electroencephalography using hybrid subdural electrodes containing macro- and microelectrode arrays. Neurosurg. Focus., 2008, 25(3), E23.
125. Anderson, W.S.; Lenz, F.A. Surgery insight: deep brain stimulation for movement disorders. Nat. Clin. Pract. Neurol., 2006, 2(6), 310-20.